A dose of vaccine plants hope and safeguards the future. This is a health gift package that benefits millions of girls - the HPV vaccine will be officially included in the national immunization plan from November 10, 2025. Girls over 13 years old born after November 10, 2011 can receive the bivalent HPV vaccine for free. This is not only a crucial step in reducing the burden of cervical cancer on families in China, but also a national commitment to promoting public health. Getting vaccinated against HPV is the first line of defense against viral invasion and prevention of cervical cancer. Cervical cancer is one of the common malignant tumors in women, posing a serious threat to their physical and mental health. In recent years, cervical cancer in China has shown a dual trend of rising incidence rate and rejuvenation. Data shows that in 2022, there were approximately 151000 new cases of cervical cancer and 56000 deaths in China. According to the policy, all regions will provide free bivalent HPV vaccine to eligible girls over the age of 13, with a total of 2 doses administered with a six-month interval. The person in charge of the Health and Immunization Department of the National Bureau of Disease Control and Prevention stated that this will effectively improve the HPV vaccination rate, reduce the differences in vaccination rates between different regions and income groups, ensure fair access to vaccination services for the target population, and protect the health of the public more widely. The determination of 13-year-old girls as the target population for free HPV vaccination in China is the optimal solution that comprehensively considers the protective effect, cost-effectiveness, and operability. An Zhijie, Deputy Director of the Immunization Center of the Chinese Center for Disease Control and Prevention, said that from the perspective of immune efficacy, vaccination with HPV vaccine at the age of 13 can achieve higher antibody levels and longer lasting protective effects. The pace of technological innovation is continuously driving the decline of health outcomes and making them more accessible to all. Wei Shuyuan, President of the China Vaccine Industry Association, introduced that the domestically produced bivalent HPV vaccines that have been launched in China are produced by two companies, with a total annual production capacity of 55 million doses, which can meet market demand and have passed the World Health Organization's pre certification. The inclusion of HPV vaccines in the national immunization program marks a new stage of development for China's immunization program. ”Wang Huaqing, Chief Expert of the Immunization Program at the Chinese Center for Disease Control and Prevention, said. As a populous country, China's decisions and practices in the prevention of cervical cancer not only safeguard women's health through practical actions, but also inject Chinese momentum into promoting more equitable and accessible global health. From surveying the number of eligible girls to setting up reasonable vaccination units, from organizing production schedules for enterprises to standardizing vaccination and risk monitoring, a healthy and fair protection network is being woven. The National Bureau of Disease Control and Prevention stated that the disease control department will work together with multiple departments to ensure the smooth implementation of policies. May more people be free from the troubles of disease, and more lives no longer wither due to cancer. Let this warm guarantee cross mountains and seas, dress girls in healthy armor, and bravely embark on a brilliant life. (New Society)